Clinical Trials Directory

Trials / Completed

CompletedNCT01382407

Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab

Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab?

Status
Completed
Phase
Study type
Observational
Enrollment
100 (actual)
Sponsor
Rambam Health Care Campus · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The hypothesis of this study is that patients who suffered from acne vulgaris during adolescence are at greater risk of developing acneiform skin rash due to cetuximab.

Detailed description

The hypothesis of this study is that patients who suffered from acne vulgaris during adolescence are at greater risk of developing acneiform skin rash due to cetuximab

Conditions

Interventions

TypeNameDescription
DRUGCetuximabOnce a week:Loading dose-400 mg/m2;subsequent-250 mg/m2 on days 8,15, 22,29,36 if administered as a single agent, or together with Irinotecan 125 mg/m2 on days 1,8,15,29 followed by administration every 42 days.

Timeline

Start date
2011-07-01
Primary completion
2017-04-01
Completion
2017-04-01
First posted
2011-06-27
Last updated
2017-04-27

Locations

2 sites across 1 country: Israel

Source: ClinicalTrials.gov record NCT01382407. Inclusion in this directory is not an endorsement.

Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab (NCT01382407) · Clinical Trials Directory